Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated cooperstown 5+1 cocktail

Journal of Clinical Pharmacology

Volumn 45, Issue 12, 2005, Pages 1413-1421

  Shelepova, Tatiana ^a   Nafziger, Anne N ^a,b   Victory, Jennifer ^b   Kashuba, Angela D M ^c   Rowland, Elizabeth ^c   Zhang, Yanhua ^d   Sellers, Edward ^d   Kearns, Gregory ^e   Steven Leeder, J ^e   Gaedigk, Andrea ^e   Bertino Jr , Joseph S ^a,b,f  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b BASSETT HEALTHCARE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e CHILDREN S MERCY HOSPITAL   (United States)

^f ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Cocktail; Cytochrome P450; Drug metabolizing enzymes; Oral contraceptives

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ETHINYLESTRADIOL PLUS NORGESTIMATE; MIDAZOLAM; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PLACEBO; VITAMIN K GROUP; WARFARIN; XANTHINE OXIDASE;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL CONTRACEPTION; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; VALIDATION PROCESS;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CONTRACEPTIVES, ORAL; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; GENOTYPE; HUMANS; MIDAZOLAM; NORGESTREL; OMEPRAZOLE; THERAPEUTIC EQUIVALENCY; VITAMIN K; WARFARIN; XANTHINE OXIDASE;

EID: 27844450558     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005280851     Document Type: Article

References (60)

1. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;113:746-750.
2. Loose-Mitchell DS, Stancel GM. Estrogens and progestins. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacologic Basis for Therapeutics. 10th ed. New York, NY: McGraw Hill; 2001:1597-1634.
3. Fotherby K. Interactions with oral contraceptives. Am J Obstet Gynecol. 1990;163:2153-2159.
4. Carter DE, Goldman JM, Bressler R, Huxtable RJ, Christian CD, Heine MW. Effect of oral contraceptives on drug metabolism. Clin Pharmacol Ther. 1974;15:22-31.
5. Ferandez-Pol JA, Zaninovich AA. Effects of administration of estrogen or diphenylhydantoin on the kinetics of dipehnylhydantoin in man. J Nucl Med. 1975;16:305-308.
6. Gupta KC, Joshi JV, Pohujani SM, Sayoskar RS. Effect of low estrogen combination oral contraceptive on metabolism of aspirin and phenylbutazone. Int J Clin Pharmacol. 1982;20:511-513.
7. Joshi JV, Gupta KC, Hazari KT, Gokral J, Pohujani S, Satoskar R. Salivary antipyrine half-life during injectable progestagen contraception. Clin Pharmacokinet. 1986;11:171-175.
8. Balogh A, Gessinger S, Svarovsky U, et al. Can oral contraceptive steroids influence the elimination of nifedipine and its primary pyridine metabolite in humans? Eur J Clin Pharmacol. 1998;54:729-734.
9. Tsunoda SM, Harris RZ, Mroczkowski PJ, Benet LZ. Preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women. J Clin Pharmacol. 1998;38:1137-1143.
10. Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Neuovonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1-hydroxylation. Br J Clin Pharm. 2000;50:333-337.
11. Belle DJ, Callaghan JT, Gorski JC, et al. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol. 2002;53:67-74.
12. Palovaara S, Tybring G, Laine K. The effect of ethinyloestradiol and levonorgestrel on the CYP2C19 mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003;56:232-237.
13. Patwardhan RV, Desmond PV, Johnson RF, Schenker S. Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med. 1980;95:603-608.
14. Kendall MJ, Quartman CP, Jack DB, Belley J. Metoprolol pharmacokinetics and the oral contraceptive pill. Br J Clin Pharmacol. 1982; 14:120-122.
15. Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol. 1982;23:129-134.
16. Abernethy DR, Divoll M, Ochs HR, Ameer B, Greenblatt DJ. Increased metabolic clearance of acetaminophen with oral contraceptive use. Obstet Gynecol. 1982;60:338-341.
17. Boekenoogen SJ, Szefler SJ, Jusko WJ. Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrin Metab. 1983;56:702-709.
18. Roberts RK, Grice J, McGuffie C, Heilbronn L. Oral contraceptive steroids impair the elimination of theophylline. J Lab Clin Med. 1983; 101:821-825.
19. Gardner MJ, Tornatore KM, Kanarkowski R, Jusko WJ. Effects of tobacco smoking and oral contraceptive use on theophylline disposition. Br J Clin Pharmacol. 1983;16:271-280.
20. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Br J Clin Pharmacol. 1985;28:425-428.
21. Koren G, Chin TF, Correia J, Tesoro A, MacLeod SM. Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. Clin Invest Med. 1985;8:222-226.
22. Kroboth PD, Smith RB, Stoehr GP, Julh RP. Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction. Clin Pharmacol Ther. 1985;38:525-532.
23. Gustavson LE, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrin Metab. 1986;62:234-237.
24. Scavone JM, Greenblatt DJ, Blyden GT. Antipyrine pharmacokinetics in women receiving conjugated estrogens. J Clin Pharmacol. 1988;28:463-466.
25. Holazo AA, Winkler MB, Patel IH. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharmacol. 1988;28:1040-1045.
26. Scavone JM, Greenblatt DJ, Locniskar A, Shader RI. Alprazolam pharmacokinetics in women on low-dose oral contraceptives. J Clin Pharmacol. 1988;28:454-457.
27. Wanwimolruk S, Kaewvichit S, Tanthayaphinant O, Suwannarach C, Oranratnachai A. Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. Br J Clin Pharmacol. 1991; 31:179-181.
28. Slayter KL, Ludwig EA, Lew KH, Middleton E Jr, Ferry JJ, Jusko WJ. Oral contraceptive effects of methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996;59:321-321.
29. Scavone JM, Greenblatt DJ, Abernethy DR, Luna BG, Harmatz JS, Shader RI. Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. J Clin Pharmacol. 1997;37:437-441.
30. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related differences. Eur J Clin Pharmacol. 1999;55:177-184.
31. Laine K, Palovaara S, Tapanainen P, Manninen P. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Clin Pharmacol Ther. 1999;66:602-608.
32. Pollock BG, Wylie M, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol. 1999;39:936-940.
33. Seidegard J, Simonsson M, Edsbacker S. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence of plasma cortisol. Clin Pharmacol Ther. 2000;67:373-381.
34. Laine K, Tybring G, Bertilsson L. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther. 2000;68:151-159.
35. McCune JS, Lindley C, Decker JL, et al. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol. 2000;41:723-731.
36. Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001;51:169-173.
37. Olubodun JO, Ochs HR, Truten V, et al. Zolpidem pharmacokinetic properties in young females: Influence of smoking and oral contraceptive use. J Clin Pharmacol. 2002;42:1142-1146.
38. Chainuvati S, Nafziger A, Leeder JS, et al. Combined phenotypic Assessment of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT2 and XO with the Cooperstown 5+1 Cocktail. Clin Pharmacol Ther. 2003;74:437-447.
39. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996;6:429-439.
40. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6:341-349.
41. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 1996;272:210-217.
42. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999;9:669-682.
43. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther. 1989;45:568-573.
44. Park YH, Kullberg MP, Hinsvark ON. Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J Pharm Sci. 1984;73:24-29.
45. Lam YW, Rodriguez SY. High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection. Ther Drug Monit. 1993;15:300-304.
46. Lagerstrom PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chrom. 1984;309:347-356.
47. Rogers JF, Morrison AL, Nafziger AN, Jones CL, Rocci ML Jr, Bertino JS Jr. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics. Clin Pharmacol Ther. 2002;72:711-717.
48. Henne KR, Gaedigk, A, Gupta G, Leeder JS, Rettie AE. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr. 1998;710:143-148.
49. Williams RL, Chen M, Hauck WW. Equivalence approaches. Clin Pharmacol Ther. 2002;72:229-237.
50. Laine K, Yasar U, Widen J, Tybring G. A screening study of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol Toxicol. 2003;93:77-81.
51. Kashuba ADM, Bertino JS Jr, Rocci ML Jr, Kulawy RW, Beck DJ, Nafziger AN. Quantitation of 3-month intraindividual variability and influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther. 1998;64:269-277.
52. Kashuba ADM, Bertino JS Jr, Kearns GL, et al. Quantitation of three-month intraindividual variability and the influence of sex and menstrual cycle phase, on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activities as determined by caffeine phenotyping. Clin Pharmacol Ther. 1998;63:540-551.
53. Kashuba ADM, Nafziger AN, Kearns GL, et al. Quantitation of long-term intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics. 1998;8:403-410.
54. Kim MJ, Bertino JS Jr, Gaedigk A, Zhang Y, Sellers EM, Nafziger AN. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther. 2002;72:192-199.
55. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187-216.
56. Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol. 1995;48:161-166.
57. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997;62:400-407.
58. Tsutsumi K, Kotegawa T, Matsuki S, et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther. 2001;70:121-125.
59. Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75:89-100.
60. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol. 2004;44:215-223.